RxDoctor Payments Data

Christopher Snyder, MD

Dermatology · Charlotte, NCNPI 1912973801

Payments from drug & device makers

$24,245in general payments, 2019–2025

Across 1,252 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$3K
  • Sun Pharmaceutical Industries Inc.$2K
  • Sanofi$2K
  • UCB, Inc.$1K
  • Lilly USA, LLC$1K
  • plus $12K from 37 others

What the payments were for

  • Speaking & faculty fees$3501%
  • Food & beverage$23,00895%
  • Education$8874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,245 in reported general payments places this provider in the 85th percentile of 475 dermatology providers in North Carolina.

See all dermatology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,019,115
Medicare patients
1,649
Services billed
13,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab59$707,146
Enbrel MiniEtanercept23$293,634
Skyrizi PenRisankizumab-Rzaa13$287,966
Dupixent SyringeDupilumab62$243,737
Cosentyx Sensoready (2 Pens)Secukinumab28$241,245
Dupixent PenDupilumab56$214,015
RinvoqUpadacitinib31$199,955
TremfyaGuselkumab14$187,768
CibinqoAbrocitinib13$72,818
OpzeluraRuxolitinib Phosphate17$34,508
VtamaTapinarof18$25,403
Clobetasol Propionate244$9,511
Tacrolimus39$8,495
Triamcinolone Acetonide415$6,942
Ketoconazole376$5,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,368$199,95531 claims
Johnson & JohnsonTremfya$2,592$187,76814 claims
PfizerCibinqo$1,177$72,81813 claims
Incyte CorporationOpzelura$743$34,50817 claims
Dermavant Sciences, Inc.Vtama$561$25,40318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 475 dermatology providers in North Carolina.

Other dermatology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →